Pharmacological therapy of osteoarthritis

Best Practice and Research: Clinical Rheumatology

Volumn 15, Issue 4, 2001, Pages 583-593

  Hochberg, Marc C ^a   Dougados, Maxime ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Acetaminophen (paracetamol); Non steroidal anti inflammatory drugs; Osteoarthritis; Pharmacological therapy

Indexed keywords

ANALGESIC AGENT; ARTHROTEC; CELECOXIB; CHONDROITIN SULFATE; CYCLOOXYGENASE 2 INHIBITOR; DIACETYLRHEIN; FAMOTIDINE; GLUCOSAMINE SULFATE; GLYCOSAMINOGLYCAN PEPTIDE; GLYCOSAMINOGLYCAN POLYSULFATE; IBUPROFEN; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PLACEBO; ROFECOXIB;

BONE PAIN; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; LONG TERM CARE; MEDICAL SOCIETY; META ANALYSIS; METHODOLOGY; NEPHROTOXICITY; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034752145     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2001.0175     Document Type: Article

References (60)

1. Recommendations for the medical management of osteoarthritis of the hip and knee
2. EULAR recommendations for the management of knee osteoarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)
3. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The second Canadian Consensus Conference
4. The evaluation of acetaminophen in the management of osteoarthritis of the knee
5. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee
6. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee
7. North of England evidence-based guideline development project: Summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis
8. Ibuprofen, acetaminophen and placebo in osteoarthritis of the knee: A six-day double-blind study
9. Arthrotec compared to acetaminophen: A clinical trial in patients with osteoarthritis of the hip or knee
10. The role of acetaminophen in the management of patients with osteoarthritis
11. Paracetamol and phenacetin
12. The relative risk of upper gastrointestinal complications among users of acetaminophen and non-steroidal anti-inflammatory drugs
13. Nonsteroid drug selectivities for cyclo-oxygenase I rather than cyclo-oxygenase 2 are associated with human gastrointestinal toxicity: A full in vitro analysis
14. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients
15. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis
16. A systematic review of randomized controlled trials of pharmacological therapy in patients with osteoarthritis of the knee
17. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee
18. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip
19. Non-steroidal anti-inflammatory drugs
20. Epidemiological assessment of the safety of conventional nonsteroidal anti-inflammatory drugs
21. The epidemiology of myocardial infarction and heart failure among users of nonsteroidal anti-inflammatory drugs
22. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: Population based observational study and case-control study
23. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta-analysis
24. Risk factors for serious nonsteroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA Trial
25. A guideline for the treatment and prevention of NSAID-induced ulcers
26. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents
27. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs
28. Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice
29. Recommendations for the clinical use of cyclooxygenase-2 specific inhibitors
30. Preliminary study of the safety and efficacy of SC-58365, a novel cyclooxygenase 2 inhibitor
31. Celecoxib for arthritis
32. Treatment of osteoarthritis with a celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
33. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib
34. Rofecoxib, a new cyclooxygenase-2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: A 6-week and a 1-year trial in patients with osteoarthritis
35. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vx ibuprofen in patients with osteoarthritis
36. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
37. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
38. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
39. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
40. Gastrointestinal toxicity with celecoxib vx nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis
41. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
42. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2 selective inhibition
43. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specific inhibitors
44. Misoprostil reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial
45. Misoprostil dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens
46. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs
47. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: A Nordic multicentre study
48. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs
49. Omepraxole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs
50. Systemic and topical treatments
51. Regulation in complementary and alternative medicine
52. Research into complementary and alternative medicine: Problems and potential
53. Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis
54. A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative
55. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: A prospective, randomized, double-blind, placebo controlled, multicenter clinical trial with a six-month treatment period and a six-month follow-up demonstrating a persistent effect
56. Diacerhein in the treatment of osteoarthritis of the hip
57. Efficacy and tolerance of diacerhein in the treatment of gonarthrosis and coxarthrosis
58. Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis
59. Effects of diacerein on the radiological progression of hip osteoarthritis: A three-year placebo-controlled study
60. Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial